Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Kimberly Lee who wrote (39942)	12/7/1999 1:17:00 PM
From: fmv503	Read Replies (1) \| Respond to of 108040

Kimberly - Your opinion of the potential of Harris short-term (next 2-3 days) including QP. Will you be holding?

To: Kimberly Lee who wrote (39942)	12/7/1999 1:19:00 PM
From: Jim B	Respond to of 108040

passed on HPOL for now... holding ANCC with limited funds.. it's one or the other.. unless I want to free up some cash from options... and I dont.. since you own them both.. I hope they both run eod .. could have sold ANCC at 43 but there's NO WAY that $43 could possibly be the top for ANCC.. i wonder if they'll get a plug on CNBC or something today (whoops.. just looked ANCC under $40 now... probably just a little shake) jim

To: Kimberly Lee who wrote (39942)	12/7/1999 1:33:00 PM
From: KevinMark	Respond to of 108040

In HPOL.

To: Kimberly Lee who wrote (39942)	12/7/1999 2:01:00 PM
From: makin_dough99	Read Replies (1) \| Respond to of 108040

NTPL- keeps moving . They can't keep it down.ACOM tomorrow!

To: Kimberly Lee who wrote (39942)	12/7/1999 2:04:00 PM
From: JD	Respond to of 108040

Bought ILXO @ 17 1. - Positive news released by U of Texas about "Campath" Leukemia treatment - news not appearing under ILXO ticker yet (ILXO owns "Campath") Monoclonal Antibody Appears Effective in Patients With Advanced B-Cell Chronic Lymphocytic Leukemia" "The data showing that CAMPATH appears both effective and relatively safe in patients who have failed all available therapies for their CLL is promising. CAMPATH reversed the course of disease progression or prevented progression in 93 percent of the study patients, and, at one year of follow-up, median survival had not been reached," said Dr. Keating. newsalert.com 2. - CANCER COMPANIES CONVENE IN SEATTLE DEC. 11 TO SHOWCASE SCIENCE, FINANCES AT INVESTORS FORUM Research news should be released under "ILXO" at least by the conference on Sat. Jerry